{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T18:11:16Z","timestamp":1789495876027,"version":"build-2803163510"},"reference-count":38,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.ijrobp.2013.05.012","type":"journal-article","created":{"date-parts":[[2013,8,3]],"date-time":"2013-08-03T02:49:46Z","timestamp":1375498186000},"page":"73-80","source":"Crossref","is-referenced-by-count":91,"title":["Increased Bowel Toxicity in Patients Treated With a Vascular Endothelial Growth Factor Inhibitor (VEGFI) After Stereotactic Body Radiation Therapy (SBRT)"],"prefix":"10.1016","volume":"87","author":[{"given":"Brandon M.","family":"Barney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetomir N.","family":"Markovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia N.","family":"Laack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert C.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jann N.","family":"Sarkaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O. Kenneth","family":"Macdonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather J.","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth R.","family":"Olivier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2013.05.012_bib1","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.bbrc.2005.05.132","article-title":"Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy","volume":"333","author":"Ferrara","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.ijrobp.2013.05.012_bib2","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2013.05.012_bib3","doi-asserted-by":"crossref","first-page":"4733","DOI":"10.1200\/JCO.2008.19.8721","article-title":"Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma","volume":"27","author":"Friedman","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2013.05.012_bib4","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2013.05.012_bib5","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1200\/JCO.2007.14.5466","article-title":"Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil","volume":"27","author":"Reck","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2013.05.012_bib6","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1001\/jama.2010.261","article-title":"Stereotactic body radiation therapy for inoperable early stage lung cancer","volume":"303","author":"Timmerman","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.ijrobp.2013.05.012_bib7","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1200\/JCO.2008.19.6329","article-title":"Multi-institutional phase I\/II trial of stereotactic body radiation therapy for liver metastases","volume":"27","author":"Rusthoven","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2013.05.012_bib8","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.radonc.2009.11.004","article-title":"Stereotactic body radiotherapy for unresectable cholangiocarcinoma","volume":"94","author":"Kopek","year":"2010","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2013.05.012_bib9","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.radonc.2008.07.019","article-title":"Stereotactic body radiotherapy for medically inoperable patients with stage I non-small cell lung cancer\u2014a first report of toxicity related to COPD\/CVD in a non-randomized prospective phase II study","volume":"88","author":"Baumann","year":"2008","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2013.05.012_bib10","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ccr.2005.07.014","article-title":"Engaging the vascular component of the tumor response","volume":"8","author":"Fuks","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ijrobp.2013.05.012_bib11","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/cncr.23209","article-title":"A prospective pilot study of curative-intent stereotactic body radiation therapy in patients with 5 or fewer oligometastatic lesions","volume":"112","author":"Milano","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2013.05.012_bib12","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S1470-2045(09)70112-3","article-title":"Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis","volume":"10","author":"Hapani","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2013.05.012_bib13","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s10456-010-9197-6","article-title":"Antiangiogenic tyrosine kinase inhibition related gastrointestinal perforations: a case report and literature review","volume":"14","author":"Walraven","year":"2011","journal-title":"Angiogenesis"},{"key":"10.1016\/j.ijrobp.2013.05.012_bib14","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1080\/02841860600904854","article-title":"Phase II study on stereotactic body radiotherapy of colorectal metastases","volume":"45","author":"Hoyer","year":"2006","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ijrobp.2013.05.012_bib15","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.ijrobp.2009.09.075","article-title":"A dosimetric model of duodenal toxicity after stereotactic body radiotherapy for pancreatic cancer","volume":"78","author":"Murphy","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2013.05.012_bib16","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1097\/COC.0b013e31821f876a","article-title":"Clinical outcomes and dosimetric considerations using stereotactic body radiotherapy for abdominopelvic tumors","volume":"35","author":"Barney","year":"2012","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2013.05.012_bib17","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.ijrobp.2007.10.059","article-title":"Universal survival curve and single fraction equivalent dose: useful tools in understanding potency of\u00a0ablative radiotherapy","volume":"70","author":"Park","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2013.05.012_bib18","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2307\/3574407","article-title":"The effect of multiple small doses of x-rays on skin reactions in the mouse and a basic interpretation","volume":"66","author":"Douglas","year":"1976","journal-title":"Radiat Res"},{"issue":"Suppl.","key":"10.1016\/j.ijrobp.2013.05.012_bib19","doi-asserted-by":"crossref","first-page":"3536","DOI":"10.1200\/jco.2006.24.18_suppl.3536","article-title":"Safety of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: updated results from a large observational registry in the US (BRiTE) [abstract]","volume":"24","author":"Hedrick","year":"2006","journal-title":"J Clin Oncol"},{"issue":"Suppl.","key":"10.1016\/j.ijrobp.2013.05.012_bib20","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.1200\/jco.2006.24.18_suppl.3535","article-title":"Risk factors for gastrointestinal perforations in patients with metastatic colorectal cancer receiving bevacizumab plus chemotherapy [abstract]","volume":"24","author":"Sugrue","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2013.05.012_bib21","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ygyno.2008.02.009","article-title":"Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II consortia","volume":"110","author":"Nimeiri","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijrobp.2013.05.012_bib22","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ygyno.2010.11.009","article-title":"Clinical predictors of bevacizumab-associated gastrointestinal perforation","volume":"120","author":"Tanyi","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijrobp.2013.05.012_bib23","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.clinre.2010.10.003","article-title":"Late anastomotic colonic dehiscence due to antiangiogenic treatment, a specific drug-class complication requiring specific treatment: an example of pazopanib complication","volume":"35","author":"Eveno","year":"2011","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.ijrobp.2013.05.012_bib24","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1200\/JCO.2007.15.8451","article-title":"Bowel perforation after radiotherapy in a patient receiving sorafenib","volume":"26","author":"Peters","year":"2008","journal-title":"J Clin Oncol"},{"issue":"Suppl.","key":"10.1016\/j.ijrobp.2013.05.012_bib25","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ijrobp.2012.07.033","article-title":"Phase I study of sorafenib and SBRT for advanced hepatocellular carcinoma [abstract]","volume":"84","author":"Dawson","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"Suppl.","key":"10.1016\/j.ijrobp.2013.05.012_bib26","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijrobp.2012.07.035","article-title":"Phase I study of sorafenib and whole-liver radiation therapy (WLRT) or stereotactic body radiation therapy (SBRT) for liver metastases [abstract]","volume":"84","author":"Brade","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2013.05.012_bib27","unstructured":"Randomized phase III study of sorafenib versus stereotactic body radiation therapy followed by sorafenib in hepatocellular carcinoma. Available at: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01730937. Accessed on April 24,\u00a02013."},{"issue":"Suppl.","key":"10.1016\/j.ijrobp.2013.05.012_bib28","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ijrobp.2009.05.071","article-title":"Radiation dose-volume effects in the stomach and small bowel","volume":"76","author":"Kavanagh","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2013.05.012_bib29","doi-asserted-by":"crossref","first-page":"132","DOI":"10.2174\/157488408784293705","article-title":"The molecular basis of class side effects due to treatment with inhibitors of the VEGF\/VEGFR pathway","volume":"3","author":"Roodhart","year":"2008","journal-title":"Curr Clin Pharmacol"},{"key":"10.1016\/j.ijrobp.2013.05.012_bib30","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s10637-008-9125-4","article-title":"Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation","volume":"26","author":"Tol","year":"2008","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.ijrobp.2013.05.012_bib31","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1093\/jnci\/djk011","article-title":"Bevacizumab-induced cardiovascular events: a consequence of cholesterol emboli syndrome?","volume":"99","author":"Mir","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ijrobp.2013.05.012_bib32","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.ijrobp.2009.02.037","article-title":"Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer","volume":"76","author":"Crane","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2013.05.012_bib33","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.ijrobp.2010.02.037","article-title":"Bevacizumab, capecitabine, amifostine, and preoperative hypofractionated accelerated radiotherapy (HypoArc) for rectal cancer: a phase II study","volume":"80","author":"Koukourakis","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2013.05.012_bib34","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.ijrobp.2010.02.030","article-title":"Phase II trial of full-dose gemcitabine and bevacizumab in combination with attenuated three-dimensional conformal radiotherapy in patients with localized pancreatic cancer","volume":"80","author":"Small","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2013.05.012_bib35","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1200\/JCO.2008.21.1771","article-title":"Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study","volume":"27","author":"Willett","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2013.05.012_bib36","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1200\/JCO.2005.03.6780","article-title":"Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer","volume":"24","author":"Crane","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2013.05.012_bib37","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.ijrobp.2005.12.004","article-title":"Increased risk of ischemic bowel complications during treatment with bevacizumab after pelvic irradiation: report of three cases","volume":"64","author":"Lordick","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2013.05.012_bib38","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1126\/science.1082504","article-title":"Tumor response to radiotherapy regulated by endothelial cell apoptosis","volume":"300","author":"Garcia-Barros","year":"2003","journal-title":"Science"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301613005440?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301613005440?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T10:39:21Z","timestamp":1596278361000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301613005440"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S0360301613005440"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2013.05.012","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]}}}